Acuitas Therapeutics’ Chief Legal Officer Miranda Lam Appointed as King’s Counsel
VANCOUVER, BC– Miranda Lam, Chief Legal Officer & Vice President, Business Development at Acuitas Therapeutics, has been appointed as King’s Counsel in British Columbia. The King’s Counsel appointment recognizes lawyers who demonstrate professional integrity, good character and excellence in the practice of law, and have distinguished themselves by their counsel and exemplary contributions to the legal profession and community at large. Only seven percent of practicing members of the B.C. bar are awarded the King’s Counsel designation at any time.
Dr. Thomas Madden, President & CEO of Acuitas Therapeutics, said, “Miranda is an exceptional legal mind and a key member of our executive team. Her commitment to professional excellence and to contributing to her community – especially in areas of diversity and inclusion – is unparalleled. On behalf of the Acuitas team, I would like to congratulate Miranda and all of the recipients of this prestigious distinction.”
Ms. Lam is an experienced commercial litigator, and before joining Acuitas, she was an equity partner at McCarthy Tétrault. She is widely recognized as a service-led business and community leader. Ms. Lam currently serves as the co-vice-chair of the Board of Governors of the University of British Columbia, as well as the boards of BC Cancer Foundation, Greater Vancouver Board of Trade, and UBC Properties Trust. A long-time champion of diversity, equity and inclusion, Ms. Lam is committed to mentorship within the legal profession. She has volunteered with several organizations, such as the Federation of Asian Canadian Lawyers, The Advocates’ Society, and as a guest lecturer at Peter A. Allard School of Law.
About Acuitas Therapeutics
Vancouver-based Acuitas Therapeutics is a private biotechnology company specializing in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles. Acuitas partners with pharmaceutical and biotechnology companies, as well as non-governmental organizations and academic institutes, to advance nucleic acid therapeutics into clinical trials and the marketplace. The team works with global partners to develop new therapies to address unmet clinical needs based on the internationally recognized capabilities of its proprietary delivery technology. Acuitas Therapeutics’ lipid nanoparticle technology is used in the Pfizer/BioNTech COVID-19 vaccine COMIRNATY®. The Acuitas team is currently working on therapeutics focused on addressing cancer, HIV/AIDS, tuberculosis, malaria and other serious diseases.
Original source here.